Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corporation disclosed that it will present an investor presentation attached as Exhibit 99.1 to this Current Report and that the presentation will be made available on the company’s investor website. The company states the presentation may be used in investor and stakeholder meetings and that the information in Item 7.01 and Exhibit 99.1 is not intended to be deemed filed under the Exchange Act or incorporated by reference in other filings unless explicitly stated.
The report also lists an interactive cover page data file as Exhibit 104. No financial statements, earnings data, or material transactions are included in this filing.